When treatment of rheumatic diseases with adalimumab fails, a physician may need to consider treatment options, such as adjusting dose or dosing intervals, switching to a different TNP blocker, or switching to a different drug agent, i.e. a non-TNF blocker. This assay specifically measures serum adalimumab levels. Several studies suggest a target adalimumab trough concentration of 5-12 mcg/mL.
The blood should be drawn just before the next infusion of
adalimumab to measure the trough drug level.
Reported (Analytical Time)
The CPT codes provided are based on AMA guidelines and are for informational purposes only.
CPT coding is the sole responsibility of the billing party.
Please direct any questions regarding coding to the payer being billed.
**This test is not available for New York patient testing** Reject Criteria: Serum Separator Tube; gross hemolysis Transport Temperature: Refrigerated Specimen Stability: Frozen (-20 degrees Celsius): 14 days Frozen (-70 degrees Celsius): 60 days Methodology: Enzyme Linked Immunosorbent Assay